The US Food and Drug Administration has opened the door to use of foreign reference products in interchangeability switching studies but suggests the extent of scientific bridging data justifying this approach might go beyond what is needed in the biosimilar context.
In its long-awaited final guidance on interchangeability, the agency no longer “strongly recommends” that sponsors use only US-licensed reference products as comparators in switching studies, as it did in...